24 April 2006
Lawrence plc
ECO Animal Health - Receipt of further Aivlosin approvals in Europe
On 22 March 2006 Lawrence plc announced that the Committee for Veterinary
Medicinal Products (CVMP) of The European Agency for the Evaluation of Medicinal
Products (EMEA) would meet in late April. At that meeting the CVMP would
consider, amongst others, two Aivlosin applications for the treatment of enteric
(digestive) diseases in pigs submitted by ECO Animal Health (ECO), a wholly
owned subsidiary of Lawrence plc.
Lawrence is delighted to report that ECO has now received positive opinions from
the CVMP on these two applications, which are for the treatment of ileitis and
swine dysentery. ECO can shortly commence the marketing of Aivlosin in the
European Union for these conditions.
These approvals represent a significant increase in the potential available
market for Aivlosin in the EU and the Group expects that they will be the
catalyst for a significant marketing initiative to be launched by its major
distributor, Schering Plough. Further EU marketing authorisations for Aivlosin
in both swine and poultry are being progressed.
Peter Lawrence, Chairman of Lawrence plc, commented:
"These approvals represent a further significant step in the marketing of
Aivlosin in Europe. Obtaining registrations is an essential but costly process
involving extensive trial work and lengthy evaluation periods; we will need to
invest significant sums to ensure that all our pharmaceutical products are
brought to market as quickly and efficiently as possible"
Contacts:
Peter Lawrence
Chairman, Lawrence plc
020 8336 2900
Anthony Spiro
Spiro Financial
020 8949 0428
Philip Davies
Charles Stanley Securities
020 7953 2457
Notes to Editors:
Lawrence plc is a leader in the development, manufacture and distribution of
principally specialist chemical and pharmaceutical products for the animal
health and farming markets worldwide. Our products for these growth markets
incorporate natural ingredients to promote well being and sustainability. We
achieve our financial goals through the careful and responsible application of
science to generate value for our shareholders.